Status:
COMPLETED
Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
40+ years
Phase:
PHASE2
Brief Summary
The primary aim of this study is to investigate the tolerability and safety of AZD 1236 compared with placebo ("inactive substance") in COPD patients by assessment of Adverse Events, vital signs and l...
Eligibility Criteria
Inclusion
- Diagnosis of COPD for 1 month
- Men or postmenopausal women
- Spirometry values indicating reduced lung function
- Smoking history equivalent to using 20 cigarettes a day for 10 years
Exclusion
- Any current respiratory tract disorders other than COPD
- Requirement for regular oxygen therapy
- Use of oral or parenteral glucocorticosteroids within 30 days prior to the study
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
74 Patients enrolled
Trial Details
Trial ID
NCT00758459
Start Date
September 1 2008
End Date
March 1 2009
Last Update
August 19 2011
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Rousse, Bulgaria
2
Research Site
Sofia, Bulgaria
3
Research Site
Helsinki, Finland
4
Research Site
Oulu, Finland